WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205633
CAS#: 69049-06-5 (HCl)
Description: Sufentanil HCl is discontinued.
MedKoo Cat#: 205633
Name: Sufentanil HCl
CAS#: 69049-06-5 (HCl)
Chemical Formula: C22H31ClN2O2S
Exact Mass: 386.2028
Molecular Weight: 423.012
Elemental Analysis: C, 62.47; H, 7.39; Cl, 8.38; N, 6.62; O, 7.56; S, 7.58
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 69049-06-5 (HCl) 56030-54-7 (free) 60561-17-3 (citrate)
Synonym: ARX02; ARX 02; ARX-02; R30730; R 30730; R-30730; Sufentanil; brand name Sufenta.
IUPAC/Chemical Name: N-(4-(methoxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide hydrochloride
InChi Key: WZGGBYJHSKVKGO-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H30N2O2S.ClH/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;/h4-10,17H,3,11-16,18H2,1-2H3;1H
SMILES Code: CCC(N(C1(COC)CCN(CCC2=CC=CS2)CC1)C3=CC=CC=C3)=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 423.012 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Motiani P, Chaudhary S, Bahl N, Sethi AK. Intrathecal sufentanil versus fentanyl for lower limb surgeries - a randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2011 Jan;27(1):67-73. PubMed PMID: 21804710; PubMed Central PMCID: PMC3146162.
2: Motiani P, Chaudhary S, Bahl N, Sethi AK. Intrathecal sufentanil versus fentanyl for lower limb surgeries - a randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):507-13. PubMed PMID: 21547180; PubMed Central PMCID: PMC3087250.
3: Hong JY, Yang SC, Yi J, Kil HK. Epidural ropivacaine and sufentanil and the perioperative stress response after a radical retropubic prostatectomy. Acta Anaesthesiol Scand. 2011 Mar;55(3):282-9. doi: 10.1111/j.1399-6576.2010.02360.x. Epub 2010 Nov 25. PubMed PMID: 21108620.
4: Zhang GH, Sun L. Peri-intubation hemodynamic changes during low dose fentanyl, remifentanil and sufentanil combined with etomidate for anesthetic induction. Chin Med J (Engl). 2009 Oct 5;122(19):2330-4. PubMed PMID: 20079135.
5: Good P, Jackson K, Brumley D, Ashby M. Intranasal sufentanil for cancer-associated breakthrough pain. Palliat Med. 2009 Jan;23(1):54-8. doi: 10.1177/0269216308100249. PubMed PMID: 19144765.
6: Bilotta F, Caramia R, Paoloni FP, Favaro R, Araimo F, Pinto G, Rosa G. Early postoperative cognitive recovery after remifentanil-propofol or sufentanil-propofol anaesthesia for supratentorial craniotomy: a randomized trial. Eur J Anaesthesiol. 2007 Feb;24(2):122-7. Epub 2006 Aug 29. PubMed PMID: 16938153.
7: Djian MC, Blanchet B, Pesce F, Sermet A, Disdet M, Vazquez V, Gury C, Roux FX, Raggueneau JL, Coste J, Joly LM. Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trial. Clin Ther. 2006 Apr;28(4):560-8. PubMed PMID: 16750467.
8: Lin CS, Lu G, Ruan LY, Gu MN. [Patient-controlled intravenous analgesia with sufentanil and fentanyl after thoracotomy: a comparative study]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Feb;26(2):240-1, 244. Chinese. PubMed PMID: 16503543.
9: El Mouedden M, Meert TF. Evaluation of pain-related behavior, bone destruction and effectiveness of fentanyl, sufentanil, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav. 2005 Sep;82(1):109-19. Epub 2005 Aug 25. PubMed PMID: 16125759.
10: Gerlach K, Uhlig T, Hüppe M, Nowak G, Schmitz A, Saager L, Grasteit A, Schmucker P. Remifentanil-propofol versus sufentanil-propofol anaesthesia for supratentorial craniotomy: a randomized trial. Eur J Anaesthesiol. 2003 Oct;20(10):813-20. PubMed PMID: 14580051.
Related CAS#
CAS#69049-06-5 (Sufentanil HCl)
CAS#56030-54-7 (Sufentanil free)
CAS#60561-17-3 (Sufentanil citrate).
